Emerging insights into Lipocalin-2: Unraveling its role in Parkinson's Disease - 23/07/24
Abstract |
Parkinson's disease (PD) ranks as the second most prevalent neurodegenerative disorder globally, marked by a complex pathogenesis. Lipocalin-2 (LCN2) emerges as a crucial factor during the progression of PD. Belonging to the lipocalin family, LCN2 is integral to several biological functions, including glial cell activation, iron homeostasis regulation, immune response, inflammatory reactions, and oxidative stress mitigation. Substantial research has highlighted marked increases in LCN2 expression within the substantia nigra (SN), cerebrospinal fluid (CSF), and blood of individuals with PD. This review focuses on the pathological roles of LCN2 in neuroinflammation, aging, neuronal damage, and iron dysregulation in PD. It aims to explore the underlying mechanisms of LCN2 in the disease and potential therapeutic targets that could inform future treatment strategies.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Lipocalin-2 levels are elevated in various tissues of Parkinson's disease patients. |
• | Lipocalin-2 promotes neuronal death through multiple pathways. |
• | Lipocalin-2 holds promise as a sophisticated biomarker for the diagnosis and prognostication of Parkinson's disease. |
Abbreviations : PD, LCN2, MMP9, STAT3, CNS, AD, BBB, LPS, TNF, TLRs, TNF-Rs, NF-κB, ROS, NOX, NHE1, ERS, UPR, PERK, EIF2α, ATF4, IL, GTP, GDP, NO, AMP, GMP, CGAS, JAK, IKK, CXCL10, IFNγ, DsDNA, CGAMP, STING, DA, MPTP, YY1, SASP, SN, DMT1, FPN1, HO-1, SOD, Nrf2, SLC3A2, WMI, DTI, SLC22A17, EGR1, ALP, DFO, LIPUS, RTMS, TDCS
Keywords : Lipocalin-2, Neutrophil gelatinase-associated lipocalin, Parkinson’s disease, Neuroinflammation, Neuroglia, Neuronal injury, Iron dysregulation
Plan
Vol 177
Article 116947- août 2024 Retour au numéro
Article précédent
- Ferroptosis in thyroid cancer: Potential mechanisms, effective therapeutic targets and predictive biomarker
- Yuying Chen, Gang Pan, Fan Wu, Yu Zhang, Yuanhui Li, Dingcun Luo
- Recent advances in biomimetic cell membrane–camouflaged nanoparticles for cancer therapy
- Sajjad Alimohammadvand, Masoumeh Kaveh Zenjanab, Milad Mashinchian, Jalal Shayegh, Rana Jahanban-Esfahlan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?